Literature DB >> 23208732

FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma.

Michael L Megison1, Jerry E Stewart, Hugh C Nabers, Lauren A Gillory, Elizabeth A Beierle.   

Abstract

Neuroblastoma, the most common extracranial solid tumor of childhood, is responsible for over 15 % of pediatric cancer deaths. We have shown that neuroblastoma cell lines overexpress focal adhesion kinase (FAK), a non-receptor protein tyrosine kinase that controls a number of tumorigenic pathways. In this study, we hypothesized that inhibition of FAK would result in decreased cellular migration and invasion in neuroblastoma cell lines, and decrease metastasis in a murine model. We utilized non-isogenic and isogenic MYCN human neuroblastoma cell lines and parallel methods of FAK inhibition. Cell viability, migration, and invasion assays were employed to assess the effects of FAK inhibition in vitro. A nude mouse model was utilized to determine the effects of FAK inhibition on in vivo liver metastasis. FAK knockdown with siRNA resulted in decreased invasion and migration in neuroblastoma cell lines, and the effects of siRNA-induced FAK inhibition were more pronounced in MYCN amplified cell lines. In addition, abrogation of FAK with a small molecule inhibitors resulted in decreased cell survival, migration and invasion in neuroblastoma cell lines, again most pronounced in cell lines with MYCN amplification. Finally, small molecule FAK inhibition in a nude mouse model resulted in a significant decrease in metastatic tumor burden in SK-N-BE(2) injected animals. We believe that FAK plays an important role in maintaining and propagating the metastatic phenotype of neuroblastoma cells, and this driver role is exaggerated in cell lines that overexpress MYCN. FAK inhibition warrants further investigation as a potential therapeutic target in the treatment of aggressive neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23208732      PMCID: PMC3625446          DOI: 10.1007/s10585-012-9560-7

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  43 in total

1.  The COOH-terminal domain of the focal adhesion kinase induces loss of adhesion and cell death in human tumor cells.

Authors:  L H Xu; X Yang; R J Craven; W G Cance
Journal:  Cell Growth Differ       Date:  1998-12

2.  A novel low-molecular weight inhibitor of focal adhesion kinase, TAE226, inhibits glioma growth.

Authors:  Qing Shi; Anita B Hjelmeland; Stephen T Keir; Linhua Song; Sarah Wickman; Dowdy Jackson; Osamu Ohmori; Darell D Bigner; Henry S Friedman; Jeremy N Rich
Journal:  Mol Carcinog       Date:  2007-06       Impact factor: 4.784

Review 3.  Focal adhesion kinase.

Authors:  I Zachary
Journal:  Int J Biochem Cell Biol       Date:  1997-07       Impact factor: 5.085

4.  Neuroblastoma: changing incidence and survival in young people aged 0-24 years. A report from the North of England Young Persons' Malignant Disease Registry.

Authors:  S J Cotterill; L Parker; L More; A W Craft
Journal:  Med Pediatr Oncol       Date:  2001-01

5.  A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.

Authors:  Vita M Golubovskaya; Carl Nyberg; Min Zheng; Frederick Kweh; Andrew Magis; David Ostrov; William G Cance
Journal:  J Med Chem       Date:  2008-12-11       Impact factor: 7.446

6.  Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines.

Authors:  Wu Huanwen; Liang Zhiyong; Shi Xiaohua; Ren Xinyu; Wang Kai; Liu Tonghua
Journal:  Mol Cancer       Date:  2009-12-21       Impact factor: 27.401

7.  Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage.

Authors:  G M Brodeur; R C Seeger; M Schwab; H E Varmus; J M Bishop
Journal:  Science       Date:  1984-06-08       Impact factor: 47.728

8.  The effect of N-myc amplification and expression on invasiveness of neuroblastoma cells.

Authors:  Y Zaizen; S Taniguchi; S Noguchi; S Suita
Journal:  J Pediatr Surg       Date:  1993-06       Impact factor: 2.545

9.  Sustained cytokine production and immunophenotypic changes in human neuroblastoma cell lines transduced with a human gamma interferon vector.

Authors:  K Uçar; R C Seeger; P M Challita; C T Watanabe; T L Yen; J P Morgan; R Amado; E Chou; T McCallister; J R Barber
Journal:  Cancer Gene Ther       Date:  1995-09       Impact factor: 5.987

10.  The omega-3 polyunsaturated fatty acid eicosapentaenoic acid inhibits mouse MC-26 colorectal cancer cell liver metastasis via inhibition of PGE2-dependent cell motility.

Authors:  G Hawcroft; M Volpato; G Marston; N Ingram; S L Perry; A J Cockbain; A D Race; A Munarini; A Belluzzi; P M Loadman; P L Coletta; M A Hull
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

View more
  28 in total

1.  A bibenzyl from Dendrobium ellipsophyllum inhibits migration in lung cancer cells.

Authors:  Chatchai Chaotham; Pithi Chanvorachote
Journal:  J Nat Med       Date:  2015-06-25       Impact factor: 2.343

2.  Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival.

Authors:  Lauren A Gillory; Jerry E Stewart; Michael L Megison; Alicia M Waters; Elizabeth A Beierle
Journal:  J Surg Res       Date:  2015-03-14       Impact factor: 2.192

3.  Monitoring focal adhesion kinase phosphorylation dynamics in live cells.

Authors:  Nur P Damayanti; Kevin Buno; Nagarajan Narayanan; Sherry L Voytik Harbin; Meng Deng; Joseph M K Irudayaraj
Journal:  Analyst       Date:  2017-07-24       Impact factor: 4.616

Review 4.  Meaningful prevention of breast cancer metastasis: candidate therapeutics, preclinical validation, and clinical trial concerns.

Authors:  Alexandra S Zimmer; Patricia S Steeg
Journal:  J Mol Med (Berl)       Date:  2014-11-22       Impact factor: 4.599

5.  Translational Strategies for Repotrectinib in Neuroblastoma.

Authors:  Tara J O'Donohue; Glorymar Ibáñez; Diego Ferreira Coutinho; Audrey Mauguen; Armaan Siddiquee; Nestor Rosales; Paul Calder; Andoyo Ndengu; Daoqi You; Matthew Long; Stephen S Roberts; Andrew L Kung; Filemon S Dela Cruz
Journal:  Mol Cancer Ther       Date:  2021-09-04       Impact factor: 6.261

6.  FAK inhibition abrogates the malignant phenotype in aggressive pediatric renal tumors.

Authors:  Michael L Megison; Lauren A Gillory; Jerry E Stewart; Hugh C Nabers; Elizabeth Mrozcek-Musulman; Elizabeth A Beierle
Journal:  Mol Cancer Res       Date:  2014-01-24       Impact factor: 5.852

7.  Induction of chemokine (C-C motif) ligand 2 by sphingosine-1-phosphate signaling in neuroblastoma.

Authors:  Mei-Hong Li; Miriam Harel; Timothy Hla; Fernando Ferrer
Journal:  J Pediatr Surg       Date:  2014-05-16       Impact factor: 2.545

Review 8.  Neuroblastoma and MYCN.

Authors:  Miller Huang; William A Weiss
Journal:  Cold Spring Harb Perspect Med       Date:  2013-10-01       Impact factor: 6.915

9.  TRPM7 maintains progenitor-like features of neuroblastoma cells: implications for metastasis formation.

Authors:  Jeroen Middelbeek; Daan Visser; Linda Henneman; Alwin Kamermans; Arthur J Kuipers; Peter M Hoogerbrugge; Kees Jalink; Frank N van Leeuwen
Journal:  Oncotarget       Date:  2015-04-20

10.  Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors.

Authors:  Michael L Megison; Lauren A Gillory; Jerry E Stewart; Hugh C Nabers; Elizabeth Mroczek-Musulman; Alicia M Waters; Jennifer M Coleman; Virginia Kelly; James M Markert; G Yancey Gillespie; Gregory K Friedman; Elizabeth A Beierle
Journal:  PLoS One       Date:  2014-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.